Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.

AZD0486 seems highly active, including in patients relapsed on Car-T therapy.

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.